IPO alert: Windlas Biotech files draft papers for IPO
Representational image/IPO
Windlas Biotech Ltd has filed preliminary papers with markets regulator Sebi for an initial public offer that includes a fresh issue of Rs 165 crore.
Besides the fresh issue, there will be an offer for sale of shares. The company is into domestic pharmaceutical formulations contract development and manufacturing business.
According to the Draft Red Herring Prospectus (DRHP), the company will also consider a pre-IPO (Initial Public Offer) placement of up to Rs 50 crore.
The proposed offer includes fresh issue of Rs 165 crore and an offer for sale of up to 5,142,067 equity shares. The latter will comprise up to 1,136,000 equity shares by the individual selling shareholder and up to 4,006,067 equity shares by the investor selling shareholder , as per the document.
Windlas Biotech, Mateon Therapeutics launch complete respiratory wellness solution
Windlas Biotech, Mateon Therapeutics launch complete respiratory wellness solution
08 March 2021 | News
Source credit: Shutterstock
Gurugram based Windlas Biotech, in partnership with Mateon Therapeutics in the US, has launched an innovative drug-device therapy PulmoHeal + ARTIHealth as a complete respiratory wellness solution.
In a first, the AI-app based platform ARTIHealth™, developed by Mateon Therapeutics will enable patients to monitor the progress of their respiratory function over time by enabling them to upload daily cough and speech recording and receiving feedback on the health of their lungs.
The platform is a self-assessment and monitoring tool that provides >90 per cent accurate feedback used for suitable self-care and remote healthcare. This is part of a long-term joint development agreement with IBM Watson Health Research and Mateon.
WHO’s Ayurveda push applauded but Indian industry calls for clearer regulations to propel growth India’s Ayurveda nutraceuticals and medicines industry players have welcomed efforts by ministers and the World Health Organization (WHO) to promote the safe and effective use of traditional medicines, but has also urged for clearer regulatory guidelines.
India’s Ministry of AYUSH recently signed a letter of exchange with the WHO South East Asia Regional (SEAR) Office in New Delhi on Monday (Feb 15), pledging to integrate these traditional practices into national health care systems.
“As a major outcome of this partnership, the Ministry of AYUSH and WHO would be working to identify various challenges faced by the member states of SEAR in regulating, integrating and further promoting traditional systems of medicine in the respective countries,” the Ministry of AYUSH said.
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW PULMOHEAL COM yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Windlas Biotech, Mateon Therapeutics partner to launch lung therapy solution
February 22, 2021
×
Developed from Artemisia extract, the active component of PulmoHeal has been known to exhibit multiple pharmacological activities against inflammation, viral infections, and lung repair. Windlas Biotech Pvt. Ltd., an Indian pharmaceutical contract drug development and manufacturing organisation partnered with Mateon Therapeutics, Inc., a US-based oncology company, launched a food supplement, and telemedicine support for respiratory wellness in India.
According to the joint official release, in India, around 100 million people suffer from respiratory problems. The key challenges are the lack of cost-effective and lab-free methods for the early diagnosis of diseases.